NEOG — NEOGEN CORP
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 711377 ·
Last close
$9.14
Market Cap
$1.99B
52W High
$11.34
52W Low
$8.16
ADV30
2,443,557
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Feb 2026 | 211,200,000 | 99,000,000 | -3,300,000 | -17,000,000 | 3,359,000,000 | 159,900,000 | 1,256,600,000 |
| Nov 2025 | 224,691,000 | 106,684,000 | -5,377,000 | -15,924,000 | 3,359,953,000 | 145,340,000 | 1,255,465,000 |
| Aug 2025 | 209,189,000 | 94,970,000 | -16,091,000 | 36,338,000 | 3,378,156,000 | 138,883,000 | 1,259,507,000 |
| May 2025 | 225,459,000 | 92,855,000 | -13,254,000 | -612,196,000 | 3,443,836,000 | 129,004,000 | 1,372,582,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$69,542,000
Investing CF
$58,571,000
Financing CF
$-101,213,000
CapEx
$-63,436,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.81
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-533,000,000
Inventory
$161,700,000
Receivables
$137,100,000
ST Investments
$0
EBIT TTM
$-565,739,000
Pretax Income TTM
$-628,058,000
Interest Exp TTM
$62,319,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$870,561,024
EBITDA
$81,262,000
Free Cash Flow
$19,474,124
Enterprise Value
$2,572,489,984
Total Cash
$159,900,000
Total Debt
$795,100,032
Shares Out
217,673,041
Trailing EPS
$-2.80
Book Value
$9.66
ROE
-25.6%
ROA
-0.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| May 2025 | 894,661,000 | -1,676,000 | -1,092,044,000 | 3,443,836,000 | 1,372,582,000 | — | 58,244,000 |
| May 2024 | 924,222,000 | 58,663,000 | -9,421,000 | 4,548,833,000 | 1,404,691,000 | — | 35,264,000 |
| May 2023 | 822,447,000 | 37,515,000 | -22,870,000 | 4,554,432,000 | 1,420,215,000 | — | 41,028,000 |
| May 2022 | 527,159,000 | 58,618,000 | 48,307,000 | 992,929,000 | 105,555,000 | — | 68,038,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.30
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | $1.76B | $12.61 | — |
| CLDX | Celldex Therapeutics, Inc. | $2.42B | $30.85 | — |
| NNNN | Anbio Biotechnology | $1.45B | $33.01 | — |
| ABSI | Absci Corp | $823.18M | $5.28 | — |
| QDEL | QuidelOrtho Corp | $817.61M | $11.99 | — |
News headlines (Yahoo Finance, 1h cache)
Can Neogen Corporation (NEOG) Become One of the Market’s Best Small-Cap Turnarounds?
2026-05-13 09:00 · Yahoo
Is Weaker Sales And Returns Reshaping The Investment Case For Neogen’s (NEOG) Valuation Assumptions?
2026-05-05 13:21 · Yahoo
1 of Wall Street’s Favorite Stock to Target This Week and 2 Facing Challenges
2026-05-02 16:36 · Yahoo
3 Reasons NEOG is Risky and 1 Stock to Buy Instead
2026-04-29 03:08 · Yahoo
Neogen’s Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
2026-04-23 12:45 · Yahoo
5 Must-Read Analyst Questions From Neogen’s Q1 Earnings Call
2026-04-16 11:30 · Yahoo
1 Unprofitable Stock on Our Watchlist and 2 Facing Challenges
2026-04-14 09:10 · Yahoo
2 Small-Cap Stocks Worth Investigating and 1 We Avoid
2026-04-13 20:28 · Yahoo
The Bull Case For Neogen (NEOG) Could Change Following Q3 Loss, Guidance Hike, Genomics Sale News
2026-04-13 02:09 · Yahoo
Assessing Neogen (NEOG) Valuation After Earnings Beat And Higher Full Year Guidance
2026-04-13 01:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.